Frequency and Evolution of Azole Resistance in<i>Aspergillus fumigatus</i>Associated with Treatment Failure1

Susan J. Howard, Daša Cerar, Michael J. Anderson, Ahmed Albarrag, Matthew C. Fisher, Alessandro C. Pasqualotto, Michél Laverdière, Maiken Cavling Arendrup, David S. Perlin, David W. Denning

Emerging infectious diseases · 2009 · 749 citations · 29 references

DOIFull text

Open access

Concepts

TL;DR

Azole antifungals are the primary oral treatment for aspergillosis, yet resistance has been sporadically reported since 1999 and is increasingly recognized as an emerging problem that can develop during therapy. In a collection of 519 isolates, 5% were resistant to itraconazole—a rise since 2004—with 65% cross‑resistant to voriconazole and 74% to posaconazole, and genetic analysis revealed 18 Cyp51A mutations (four novel) and evidence that resistant mutants evolved from susceptible strains.

Abstract

Abstract Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has been reported infrequently. The first resistant isolate was detected in 1999 in Manchester, UK. In a clinical collection of 519 A. fumigatus isolates, the frequency of itraconazole resistance was 5%, a significant increase since 2004 (p<0.001). Of the 34 itraconazole-resistant isolates we studied, 65% (22) were cross-resistant to voriconazole and 74% (25) were cross-resistant to posaconazole. Thirteen of 14 evaluable patients in our study had prior azole exposure; 8 infections failed therapy (progressed), and 5 failed to improve (remained stable). Eighteen amino acid alterations were found in the target enzyme, Cyp51A, 4 of which were novel. A population genetic analysis of microsatellites showed the existence of resistant mutants that evolved from originally susceptible strains, different cyp51A mutations in the same strain, and microalterations in microsatellite repeat number. Azole resistance in A. fumigatus is an emerging problem and may develop during azole therapy.

References

29